Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. (Q53098953)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. |
scientific article |
Statements
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. (English)
Claudia Haferlach
1 reference
Susanne Schnittger
1 reference
Alice Fabarius
1 reference
Gerhard Ehninger
1 reference
Hermann Einsele
Michael Pfreundschuh
Rüdiger Hehlmann
Martin C Müller
Benjamin Hanfstein
Annette Schreiber
Ulrike Proetel
Nadine Pletsch
Markus Pfirrmann
Jolanta Dengler
Christiane Falge
Lothar Kanz
Andreas Neubauer
Michael Kneba
Frank Stegelmann
Cornelius F Waller
Karsten Spiekermann
Gabriela M Baerlocher
Dominik Heim
Hermann Heimpel
Christoph Nerl
Stefan W Krause
Dieter K Hossfeld
Hans-Jochem Kolb
Joerg Hasford
Susanne Saußele
2 December 2013
32
5
415-423